The NOAC Education platform contains a range of free, digital activities where top experts in stroke prevention provide digestible information and guidance on managing practical issues that arise in patients receiving anticoagulation.
NOAC Education provides time-pressed clinicians a convenient, tailored learning experience: live 30-minute webinars (Journal Clubs) with a unique opportunity to pose questions to authors of novel and practice changing studies, archived Journal Clubs webinars to watch anytime, recordings of NOAC Education symposia at international conferences events and expert-led case study resolution videos.
Moreover, the NOAC Education activities are available as instant open-access eLearning for those short on time or as a registered accredited eLearning for accruing CPD points – allowing clinicians to stay-up-to date with the latest in anticoagulation in the format and duration that is most valuable to them.
Brand new: NOAC Myth-buster
Animation video dispelling common misconceptions. The animation will cover a visual illustration of non-specific reversal of anticoagulation by prothrombin complexes (PCCs) and understanding of newer specific reversal by fXa inhibitors.
Brand new: NOAC poster sessions
A unique opportunity to review scientific posters and pose questions on study methodology, results and learning lessons directly to the expert study author and chair Professor John Camm for an informative analysis of the data.
Poster 1: Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in non-valvular atrial fibrillation – a cohort study in the 3 Scandinavian countries – Professor Søren Paaske Johnsen
Poster 2: Modifications of renal function in atrial fibrillation patients treated with different oral anticoagulants: a multicentre cohort stud – Assistant Professor Daniele Pastori
Ongoing Journal Club series looking at the latest studies and the implications for improved clinical practice:
- Having covered the ANNEXA-4 interim analysis in a past NOAC Journal Club, the latest webinar will see study author Dr Stuart Connolly discuss the full study results where the performance of first-in-kind fXa inhibitor reversal agent andexanet alfa is evaluated for safety and effectiveness criteria in patients with acute major bleeding.
- Join Dr John Eikelboom who will discuss a pivotal study on 2,200 patients. Of these patients with atherosclerosis requiring anticoagulation, an association was seen between anticoagulant-induced gastrointestinal or genitourinary bleeding and higher rates of cancer.
Access the NOAC Education platform now to access this indispensable educational resource.
You can also sign-up to the NOAC eNewsletter to be informed of newly-released NOAC Education activities.